The S&P/ASX 200 Index (ASX: XJO) may be having a subdued year so far, but that hasn’t stopped some ASX 200 shares from delivering very impressive gains.

For example, the three ASX 200 shares in this article are up over 30% since the start of the year. Here’s why:

BHP Group Ltd (ASX: BHP)

The BHP share price is up approximately 34% so far in 2026. The main driver of this has been the mining giant’s growing exposure to copper. While iron ore remains important, copper became its largest contributor to earnings during the first half of FY 2026. And with BHP continuing to focus on expanding its production output and copper prices hitting record highs this year, this bodes well for its earnings and ultimately its dividends.

Codan Ltd (ASX: CDA)

The Codan share price is up almost 50% since the start of the year. This technology company’s shares have been on fire in 2026 thanks to a very impressive performance. In April, management revealed that its performance in the second half had been stronger than expected. As a result, it now expects FY 2026 EBIT to hit $235 million and net profit to reach $170 million. This represents an increase of over 60% from last year. It said: “In DTC, strong demand from defence customers for unmanned systems, supported by ongoing geopolitical tensions, continues to drive growth in our software-defined radios (SDRs). As a result, the Communications business is expected to achieve revenue growth at the top end of the 15% to 20% range for the full year FY26.”

PLS Group Ltd (ASX: PLS)

The PLS share price has raced almost 40% higher so far this year. Investors have been fighting to get hold of the lithium giant’s shares after the price of the battery-making ingredient increased materially. This has led to PLS generating huge profit growth so far in FY 2026. For example, its third-quarter update revealed a 12% quarter-on-quarter increase in spodumene concentrate production to 232.4kt for the three months. And with its realised price increasing 61% to US$1,867 per tonne, the company reported a 52% jump in revenue to A$567 million. But it gets better. As its costs reduced to A$520 per tonne, this led to a cash margin from operations of A$461 million. This represents a 178% increase quarter-on-quarter. This is quite a turnaround. It wasn’t long ago that lithium prices were in the doldrums and the company was close to operating at a loss.

The post BHP and these ASX 200 shares are up 30%+ in 2026 appeared first on The Motley Fool Australia.

More reading

• ASX 200 iron ore shares down 5%: Should you buy the dip?
• BHP shares hit a record high this week. Is the rally about to crack?
• 3 ASX 200 mining shares to buy: experts
• 7 ASX 200 shares with strengthened buy ratings this week
• Why CBA, PLS, Resolute Mining, and Silver Mines shares are dropping today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It has been a busy week for many of Australia’s top brokers. This has led to a number of broker notes hitting the wires.

Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone right now:

IperionX Ltd (ASX: IPX)

According to a note out of Bell Potter, its analysts have retained their speculative buy rating and $8.25 price target on this titanium production technologies company’s shares. This follows the announcement of a definitive feasibility study for its 100%-owned Titan Critical Minerals project located in Tennessee, USA. Bell Potter was pleased with the study and highlights that it is permitted, shovel-ready, and strategically important to the US as a domestic source of critical minerals supply. Outside this, the broker likes IperionX due to its belief that it has the potential to disrupt the incumbent titanium supply chain through materially lowering production costs and manufacturing waste. It also expects the company to benefit from increased defence sector spending. The IperionX share price is trading at $5.44 this afternoon.

Megaport Ltd (ASX: MP1)

A note out of UBS reveals that its analysts have retained their buy rating on this network solutions company’s shares with an improved price target of $24.20. The broker has been impressed with Megaport’s acquisition of Latitude.sh. It points out that it has materially strengthened the company’s earnings outlook. In fact, it notes that contracts secured since November have annual recurring revenue 6 times larger than the acquired business. And with accelerating AI and cloud demand, cross-selling opportunities, and balance sheet capacity, UBS believes it is well-positioned to win further contracts. It also believes there is upside potential if AI adoption continues to drive demand. The Megaport share price is fetching $18.20 at the time of writing.

Treasury Wine Estates Ltd (ASX: TWE)

Analysts at Citi have upgraded this wine giant’s shares to a buy rating with an improved price target of $5.50. According to the note, the broker was pleased with the Penfolds owner’s investor day update. It believes Treasury Wine’s medium term outlook is more positive now after management laid out plans to simplify its portfolio. Citi notes that this plan is expected to result in earnings margins comfortably ahead of prior expectations. The Treasury Wine share price is trading at $4.70 on Friday afternoon.

The post Brokers name 3 ASX shares to buy right now appeared first on The Motley Fool Australia.

More reading

• Why Chalice Mining, CSL, Megaport, and Pro Medicus shares are racing higher
• 7 ASX 200 shares with strengthened buy ratings this week
• Brokers name 3 ASX shares poised for 52% to 78% gains
• 3 ASX 200 stocks racing higher in this week’s slumping market
• Up 183% since April, why the Megaport share price is tipped to keep charging higher

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Megaport and Treasury Wine Estates. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Megaport and Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) iron ore shares have fallen heavily over two days on news that production is rapidly rising at the massive Simandou project.

Over the past two days, BHP Group Ltd (ASX: BHP) shares have fallen 5.25% to $61.56.

The Fortescue Ltd (ASX: FMG) share price has declined 6.41% to $20.59.

Rio Tinto Ltd (ASX: RIO) shares are down 5.03% to $185.19.

ASX 200 iron ore small-cap share, Champion Iron Ltd (ASX: CIA), has decreased 5.21% to $4.28 apiece.

More about Simandou

Simandou, located in the Republic of Guinea, Africa, is the largest undeveloped high-grade iron ore deposit in the world.

It is majority-owned by Chinese interests, but Rio Tinto also owns a substantial stake.

Simandou is divided into four blocks. Blocks 1 and 2 are operated by a consortium backed by Chinese companies.

Blocks 3 and 4 are operated by Rio Tinto and its partners, the Government of Guinea, and Chalco Iron Ore Holdings, which is a Chinese state-owned consortium.

China is keen to diversify its iron ore supply away from Australia to reduce costs, and developing its own mine is one answer.

Operations began in November, and 0.6 million tonnes of iron ore were shipped in each of the first three months of 2026.

Then came a big jump to 1.3 million tonnes in April, followed by another leap to 2.2 million tonnes in May, according to Bloomberg.

While higher production bodes well for Rio Tinto, it also increases global supply, which can negatively impact the iron ore price.

Iron ore price tumbles to 7-week low

The iron ore price is at a 7-week low of US$102 per tonne on Friday.

The commodity’s value has fallen 6.5% over the week and is down 4.8% in the calendar year to date.

Trading Economics analysts said “abundant global supplies” and “weakening demand” are weighing on the iron ore price.

The analysts explained:

Industry data showed that shipments from Australia and Brazil remained near a two-year high, while iron ore inventories at Chinese ports stayed elevated, reinforcing concerns about oversupply.

On the demand side, recent figures indicated that blast furnace utilization rates in China were steady, while steel mill profitability have declined, pointing to softer industry conditions.

Adding to the pressure, the steel market entered its traditional seasonal slowdown earlier than usual this year, as persistent rainfall and an early onset of summer heat curtailed outdoor construction activity, weakening demand for steel products.

Should you buy the dip on ASX 200 iron ore shares?

The long-term outlook for Australian mining remains strong. Experts say a new commodities super cycle is now underway.

However, iron ore will not be a key feature of the next mining boom like it was in the early 2000s to 2013.

That boom was driven by China’s rapid industrialisation, and in particular, property development.

Today, China’s property market is hopelessly oversupplied and home prices are falling.

However, China still needs our iron ore for many industrial uses, including the production of steel, which it is increasingly exporting.

In terms of whether you should buy this week’s dip on ASX 200 iron ore shares, here is some information to help you.

Buy, hold, sell?

According to the TradingView platform, the consensus rating among 18 analysts on BHP shares is neutral (or hold).

The analysts have a 12-month target share price range of $39.37 to $68.51 for BHP stock.

The consensus rating among 16 analysts on Rio Tinto shares is neutral.

They have a target price range of $140.52 to $207.46.

The consensus rating among 17 analysts on Fortescue shares is sell.

They have a 12-month target price range of $15.91 to $23.83.

The consensus rating among 8 analysts on Champion Iron shares is buy.

They have a target price range of $4.60 to $7.70.

The post ASX 200 iron ore shares down 5%: Should you buy the dip? appeared first on The Motley Fool Australia.

More reading

• BHP shares hit a record high this week. Is the rally about to crack?
• 3 ASX 200 mining shares to buy: experts
• 7 ASX 200 shares with strengthened buy ratings this week
• Buy, hold, sell: IPD, Kogan, Rio Tinto shares
• 3 ASX shares Warren Buffett would probably love right now

Motley Fool contributor Bronwyn Allen has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BHP Group Ltd (ASX: BHP) shares have finally taken a breather after a huge run.

At the time of writing, the BHP share price is down 2.15% to $61.45.

That follows Wednesday’s all-time high of $65.04, which capped off a solid rally for Australia’s largest mining company.

Even after today’s fall, BHP shares are still up 35% in 2026 and around 62% over the past year.

So, after such a strong run, investors have a fair question to ask.

Is there still room for BHP shares to move higher, or has the easy money already been made?

Profit takers move in after record high

Today’s fall looks like a mix of profit-taking and caution around commodity prices.

BHP had been running hard into record territory, so some selling was always possible once the stock hit a new high.

Iron ore is also back in focus. It remains a major driver of BHP’s earnings and cash flow, despite the company’s growing focus on copper.

The iron ore price has softened recently, falling to around US$101.96 a tonne.

It is still higher than a year ago, but the recent pullback has been less supportive for the big miners.

There are also fresh concerns around supply, with investors watching rising exports from Guinea’s giant Simandou iron ore project.

BHP’s copper push remains a key focus

The bull case for BHP is not only about iron ore.

Copper has become a much bigger part of BHP’s outlook.

BHP has been increasing its exposure to copper, which is tied to electricity networks, data centres, renewable energy, industrial growth, and electric vehicles.

The company lifted its FY26 copper production guidance earlier this year to between 1.9 million tonnes and 2 million tonnes.

BHP later said strong performance at Escondida and Antamina supported production in the upper half of that guidance range.

Copper now has a larger role in BHP’s earnings mix, particularly when iron ore prices are moving around.

BHP has also said copper demand could rise from around 34 million tonnes a year today to more than 50 million tonnes by 2050.

At the same time, bringing new copper supply to market is difficult, expensive, and painfully slow.

BHP is no longer cheap

The harder question for investors now is BHP’s current valuation.

The company has a market capitalisation of about $312 billion.

It also trades on a price-to-earnings (P/E) ratio of about 21.8, with a dividend yield of roughly 3.2%.

Those numbers still leave room for the stock to rise.

But after a 62% gain over the past year, investors are paying a much higher price than they were a year ago.

Germany’s DZ Bank recently upgraded BHP to a hold rating and placed a $65 price target on the stock.

The target is only slightly above today’s share price.

It suggests DZ Bank still likes the business, but sees less room for the share price to run.

The post BHP shares hit a record high this week. Is the rally about to crack? appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares with strengthened buy ratings this week
• 3 ASX shares Warren Buffett would probably love right now
• If I invest $5,000 in BHP shares, how much passive income will I receive in 2026 and 2027?
• How much super do you actually need to retire in Australia? The answer might surprise you
• 7 ASX shares attracting upgraded ratings this week

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week in the red. At the time of writing, the benchmark index is down 0.6% to 8,632.8 points.

Four ASX shares that are not letting that hold them back today are listed below. Here’s why they are storming higher:

Chalice Mining Ltd (ASX: CHN)

The Chalice Mining share price is up 5% to $1.56. This may be a delayed reaction to the release of a promising announcement from the mineral exploration company on Thursday. Chalice Mining reported significant new results from rock chip sampling and ground geophysics at the recently defined Deep Blue Copper-Molybdenum-Silver-Rare Earth Element (REE) target. It highlights that “highly anomalous Cu-REE results in rock chips [were] taken in area of isolated outcrop, within a ~2.5km long, coherent copper-molybdenum-silver soil anomaly.”

CSL Ltd (ASX: CSL)

The CSL share price is up 5% to $97.58. This appears to have been driven by relative strength in the healthcare sector on Friday. In addition, it is worth noting that CSL revealed some insider buying this morning. Its director, Carolyn Hewson AO, picked up almost $100,000 worth of CSL shares through an on-market trade this week.

Megaport Ltd (ASX: MP1)

The Megaport share price is up 9% to $18.16. Investors have been buying this network solutions company’s shares following the completion of an institutional entitlement offer. Megaport raised approximately $518 million at $14.30 per share. This represents a 13.9% discount to its last close price. In addition, Megaport revealed that it has secured four new AI infrastructure contracts with combined Total Contract Value (TCV) of approximately $458.9 million. The company’s CEO, Michael Reid, said: “This exceptional outcome reflects the strong support of our institutional shareholders and their confidence in our strategy. By combining Megaport’s global footprint of more than 1,100 data centres in 31 countries with Latitude.sh’s platform capabilities, we are building a Globally-Distributed AI Inference Cloud designed to support AI at global scale. We now look forward to our retail shareholders having the same opportunity to participate on a pro rata basis. We’re just getting started. Game on!”

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is up 4% to $165.90. Yesterday, this health imaging technology company advised that its Visage Imaging business signed a five-year, A$16 million contract renewal with The Ohio State University Wexner Medical Center (OSUWMC). This includes the additions of Visage 7 Workflow and Visage 7 Cardiology Imaging. Pro Medicus’ CEO, Dr Sam Hupert, said: “OSUWMC provides world class, acclaimed patient care. Renewing this contract, to now include the additions of Visage 7 Workflow and Visage 7 Cardiology Imaging, confirms our belief that we have extensive native capabilities that Visage customers appreciate as they seek to retire legacy solutions and continue to scale their Visage 7 Enterprise Imaging Platform.”

The post Why Chalice Mining, CSL, Megaport, and Pro Medicus shares are racing higher appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares with strengthened buy ratings this week
• 6 ASX 200 shares downgraded by analysts this week
• 3 ASX 200 stocks racing higher in this week’s slumping market
• Up 183% since April, why the Megaport share price is tipped to keep charging higher
• ‘Game on!’ Why Megaport shares are rocketing 27% today

Motley Fool contributor James Mickleboro has positions in CSL, Megaport, and Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Megaport. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are down 0.67% to 8,627.9 points on Friday.

Among the 11 market sectors, the beaten-up healthcare sector is in the lead today, up 3.1%, while materials is the laggard, down 2.1%.

The materials sector is dominated by ASX 200 mining shares, which are falling on fears of lower iron ore export earnings.

However, the long-term outlook for mining remains positive. Experts say a new commodities super cycle is underway.

However, iron ore is unlikely to outperform in this next mining boom for Australia, given softening demand from China.

Let’s take a look at three ASX 200 mining shares with buy ratings from the experts.

Rio Tinto Ltd (ASX: RIO)

The Rio Tinto share price is $185.50, down 1.4% on Friday and up 33% over the past six months.

Rio Tinto and other ASX 200 iron ore mining shares have experienced heavy two-day falls on news of ramped-up production at Simandou.

Production began six months ago at the African iron ore project, which is the world’s largest undeveloped high-grade iron ore deposit.

While the new production is beneficial for Rio Tinto, the extra supply is negatively affecting the global iron ore price.

The commodity slipped below US$102 per tonne today, and has fallen 6.5% this week.

JP Morgan renewed its buy rating on Rio Tinto shares on Tuesday.

The broker lifted its 12-month price target from $203 to $207.

This suggests a potential 12% upside ahead.

PLS Group Ltd (ASX: PLS)

The PLS Group share price is $5.97, down 2.8% on Friday.

Over the past six months, this ASX 200 lithium share has ripped 57%.

RBC Capital renewed its buy rating on PLS Group shares this week.

The broker raised its price target from $5.40 to $7.

This suggests a potential 18% upside ahead.

Formerly known as Pilbara Minerals, the stock hit a record $6.81 on Monday.

Lithium prices are rebounding strongly in 2026. The carbonate price is up 42% year to date and 179% year over year.

Newmont Corporation CDI (ASX: NEM)

The Newmont share price is $149.01, down 1% on Friday.

Over the past month, this ASX 200 gold share has dipped 2.4%.

UBS assigned a buy rating to Newmont shares with a $195 target on Monday.

This suggests a potential 31% upside ahead.

Gold has been on an amazing multi-year run, but growth in the gold price stalled this year.

Find out why the gold price has fallen 17% since the Iran war began.

The post 3 ASX 200 mining shares to buy: experts appeared first on The Motley Fool Australia.

More reading

• Why CBA, PLS, Resolute Mining, and Silver Mines shares are dropping today
• Buy, hold, sell: IPD, Kogan, Rio Tinto shares
• 5 things to watch on the ASX 200 on Friday
• 3 ASX 200 shares reporting major insider buying and selling
• Forget Newmont, this ASX gold stock could rise 50%

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are down 0.66% to 8,629.1 points on Friday.

Brokers have indicated continuing confidence in several ASX 200 shares this week.

Let’s take a look.

BHP Group Ltd (ASX: BHP)

The BHP Group share price is $61.52, down 2% today.

BHP shares hit a new record price of $65.04 on Wednesday.

On Thursday, BHP and other ASX 200 iron ore mining shares fell heavily on news of ramped-up production at Simandou.

The Simandou iron ore project in Africa is the world’s largest untapped, high-grade iron ore deposit.

Morgan Stanley reiterated its buy rating on BHP shares on Monday.

The broker has a price target of $67.50, suggesting almost 10% upside remains.

Megaport Ltd (ASX: MP1)

Megaport shares are flying on Friday, up 9.6% to $18.18 apiece.

The Megaport share price is the fastest riser of the entire ASX 200 today.

In earlier trading, the ASX 200 tech share reached a new 52-week high of $21.16.

Megaport shares came out of a trading halt today after the company completed the institutional component of a $827.3 million fully underwritten entitlement offer.

Earlier this week, Megaport announced four new AI infrastructure contracts worth approximately $458.9 million.

The contracts require approximately $369.5 million of capital expenditure, hence the capital raise.

UBS renewed its buy rating on Megaport shares today.

The broker raised its 12-month price target from $16.70 to $24.20.

This suggests a potential 33% upside ahead.

Pro Medicus Ltd (ASX: PME) 

The Pro Medicus share price is $165.48, up 3.9% today.

Over the past month, this ASX 200 healthcare share has soared 21%.

Macquarie maintained its buy rating on Pro Medicus shares with a $221 target this week.

This suggest a potential 34% upside ahead.

Find out why another expert considers Pro Medicus shares the ‘most defensively positioned software business’ on the ASX.

AMP Ltd (ASX: AMP)

The AMP share price is $1.51, up 2.2% today.

This ASX 200 financial share has fallen 17% in the calendar year to date (YTD).

Citi renewed its buy call on AMP shares with a $1.80 target this week.

This implies potential capital growth of 19% over the next year.

IAG Australia Group Ltd (ASX: IAG)

The IAG share price is $7.55, up 0.1% today and down 5.5% YTD.

UBS reiterated its buy rating on IAG shares with an $8.80 target on Monday.

This implies a potential 17% upside ahead.

Qantas Airways Ltd (ASX: QAN)

The Qantas share price is $9.19, up 0.4% today.

This ASX 200 airline share has lifted 9% over the past month.

Goldman Sachs renewed its buy rating on Qantas shares with a $12.25 target.

This implies potential capital growth of 33% over the next year.

South32 Ltd (ASX: S32)

The South32 share price is $4.64, down 2.2% today.

Over the past month, this ASX 200 mining share has ripped 14% higher.

Morgan Stanley reaffirmed its buy rating on South32 shares with a $4.85 target.

This suggests a potential 4% upside ahead.

The post 7 ASX 200 shares with strengthened buy ratings this week appeared first on The Motley Fool Australia.

More reading

• BHP shares hit a record high this week. Is the rally about to crack?
• Why Chalice Mining, CSL, Megaport, and Pro Medicus shares are racing higher
• 3 ASX 200 stocks racing higher in this week’s slumping market
• Up 183% since April, why the Megaport share price is tipped to keep charging higher
• How to become rich by investing in ASX shares

Motley Fool contributor Bronwyn Allen has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Macquarie Group, and Megaport. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended BHP Group and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The new financial year is only a few weeks away.

I think that makes this a good time to look for ASX shares that could be best buys before FY27 begins.

The three shares in this article have strong long-term opportunities and I think they could be worth considering for investors.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix Pharmaceuticals is one ASX share I would buy for FY27.

The company operates in radiopharmaceuticals, which is one of the more interesting areas of healthcare in my view. It is focused on products that can help detect and treat cancer more precisely.

That is the part of the story I find most compelling. Cancer care is moving towards better targeting, earlier detection, and more personalised treatment. Telix is exposed to that shift through imaging products, targeted therapies, and a growing pipeline.

This is not a simple healthcare stock. It carries clinical, regulatory, manufacturing, and commercial risks. The market can also change its view quickly when expectations around high-growth biotech companies move.

But I think Telix has already moved beyond being a purely speculative story. It has commercial products, global ambitions, and a pipeline that could become more valuable over time if management keeps executing.

FY27 could be another important year for the company as investors look for more evidence that Telix can turn its scientific position into durable earnings growth.

Catapult Sports Ltd (ASX: CAT)

Catapult Sports is another ASX share I think could be worth buying before FY27.

The company sells technology used by elite sporting teams to understand performance, training, tactics, workload, and recovery.

What interests me is how embedded this kind of technology can become inside a professional sports organisation. Clubs want information that helps coaches plan sessions, medical teams manage injury risk, analysts review performance, and players prepare more effectively.

That daily-use element is important.

I also think Catapult is becoming a more complete sports technology platform. Wearables remain part of the story, but the opportunity is broader across video, athlete monitoring, analysis, and workflow tools.

Elite sport is also global. Football, basketball, rugby, cricket, American football, and many other codes all want better information. The company does not need to win every team in every league to build a much larger business. It just needs to keep deepening its value with customers and expanding carefully.

ResMed Inc (ASX: RMD)

ResMed is the third ASX share I would buy for FY27.

The sleep health giant has been under pressure, but I think the long-term case remains attractive.

ResMed sells devices, masks, accessories, software, and connected care products for sleep apnoea and other respiratory conditions. But treatment does not necessarily end with a single sale. Patients often need replacement masks, ongoing support, monitoring, and long-term therapy management.

Sleep apnoea remains significantly underdiagnosed, but greater awareness of the condition has been encouraging more people to seek diagnosis over time. ResMed’s leadership position, strong brand, scale, distribution, and product depth position it to win if that continues.

Foolish takeaway

The start of a new financial year can be a useful moment to reassess what kind of businesses are worth owning for the years ahead.

I am drawn to companies that are solving real problems in markets that still have room to grow. Cancer detection and treatment, elite sports performance, and sleep health all fit that description.

I think each of these ASX shares has enough long-term potential to be worth buying before the new financial year begins.

The post Which are the best ASX shares to buy now for FY27? appeared first on The Motley Fool Australia.

More reading

• Canaccord Genuity has just added these two ASX 200 shares to its best ideas list
• Here are the top 10 ASX 200 shares today
• Why Catapult Sports, Harvey Norman, Inghams, and Opthea shares are sinking today
• 3 ASX 200 healthcare shares to buy while they’re on sale
• Are CSL and ResMed shares buys at 52-week lows?

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended Catapult Sports and ResMed. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is heading south on Friday.

At the time of writing, the benchmark index is down 0.62% to 8,632 points.

The index has fallen from a day high of 8,705 points and is now trading near its session low of 8,613.6 points.

That follows Thursday’s 1.13% fall, which left the ASX 200 at 8,686.1 points.

But here’s the interesting part.

The market is not falling because every part of the ASX 200 is being sold off.

At the latest check, 91 stocks were lower, 99 were higher, and 10 were unchanged.

So why is the index still in the red?

The big end of the market is doing the damage

The weakness is coming from some of the largest names on the ASX.

BHP Group Ltd (ASX: BHP) shares are down 1.93% to $61.59, while Rio Tinto Ltd (ASX: RIO) shares are down 1.24% to $185.74.

Fortescue Ltd (ASX: FMG) is also under pressure, with its shares down 2.24% to $20.55.

Energy stocks are not helping either.

Woodside Energy Group Ltd (ASX: WDS) shares are down 1.69% to $30.80.

Commodity prices are adding to the pressure. Gold is down 0.83% to US$4,437 an ounce, copper is off 1.61% to US$6.40 per pound, and iron ore has fallen 1.69% to US$101.96 a tonne.

Commonwealth Bank of Australia (ASX: CBA) shares are slipping 1.56% to $161.17, while Westpac Banking Corp (ASX: WBC) shares are 1.39% lower at $34.75.

The banks are also weighing on the index.

National Australia Bank Ltd (ASX: NAB) shares are shedding 0.73% to $36.74, and ANZ Group Holdings Ltd (ASX: ANZ) shares are drifting 1.04% lower to $34.12.

Healthcare and tech are helping limit the fall

The other side of today’s session is more positive.

Healthcare shares are among the better performers, with CSL Ltd (ASX: CSL) up 4.59% to $96.84.

Cochlear Ltd (ASX: COH) shares are also higher, rising 5% to $99.85.

ResMed Inc (ASX: RMD) shares are lifting 3.47% to $27.42, while Pro Medicus Ltd (ASX: PME) shares are 3.66% higher at $165.06.

There are also some strong moves in tech and growth names.

Megaport Ltd (ASX: MP1) shares are soaring 10.36% to $18.33, making it one of the standout names on the ASX.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are also higher, rising 5.35% to $13.58.

These gains are helping stop the ASX 200 from looking worse, but they’re not enough to offset pressure from the larger index heavyweights.

The post Why is the ASX 200 falling when so many stocks are rising? appeared first on The Motley Fool Australia.

More reading

• Atlas Arteria reiterates ‘reject’ on IFM bid, maintains 2026 distribution guidance
• Perpetual to acquire Interfi majority stake; debt reduction underway
• Megaport completes $518m institutional entitlement offer
• Monadelphous Group wins $380m energy contract
• Meridian Energy: draft approval for Lake PÅ«kaki hydro storage

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, Megaport, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended BHP Group, CSL, Cochlear, Pro Medicus, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Canaccord Genuity has just published the latest edition of its Invest Now publication, in which it lists its “highest conviction investment ideas”.

They’ve named two new ASX 200 shares in this list, which I’ll get to shortly.

First, let’s look at their broader take on the economy.

Relief rally could be on the way

As a starter, they are basing their outlook on a solution to the Middle East conflict, which has been in a stalemate for some weeks now.

As they said:

A Middle East resolution in the relatively near future remains our central case. Both sides ultimately have strong incentives to negotiate a deal. There is still a decent but finite buffer of energy product reserves, but the clock is ticking on a deal being struck in coming weeks.

CG said that a truce would see a bigger “relief rally” in markets outside of the US, in their opinion, “however the global growth outlook has undoubtedly been tempered by the events in the Middle East, which should favour the tech-led US market at the margin once any short-term relief rally has faded”.

In Australia, CG said the underperformance of the local market versus global equities since the market’s February highs has been “stark”.

They said:

The initial period of relative underperformance in March was related to Australia’s perceived sensitivity to a global energy shock as the outbreak of the US-Iran war saw investors move to price significant downside risks for the global economy. While Australia is well ahead of its late March lows, the local rebound has been held back by a number of factors.

These include a lack of technology exposure, rising domestic macroeconomic concerns, and some disappointing earnings announcements.

ASX 200 shares to consider

In terms of the stocks they like in this scenario, they have added Aristocrat Leisure Ltd (ASX: ALL) and TechnologyOne Ltd (ASX: TNE) to their list.

They said their conviction in Aristocrat had improved materially since its “broadly in-line” first-half result.

They added:

The result suggests the business has returned to consistent execution and double‑digit earnings growth, while importantly demonstrating that it continues to gain share in US land-based gaming, which is key to our thesis. Pleasingly, iGaming momentum also remains strong as the high-growth segment scales towards its US$1bn FY29 revenue target.

With regards to TechnologyOne, they said it was a high-quality software business, “with a deeply embedded customer base across key verticals including government and education”.

They added:

The company’s operational momentum is strong, with FY26 tracking towards the top end of guidance and FY27 is shaping up as another ~20% profit before tax growth year. We remain confident in TNE’s resilience against AI disruption, runway for growth, supported by earnings upgrades from its AI tool Plus.

Other companies in CG’s favoured list locally include Alcoa Corporation (ASX: AAI), Evolution Mining Ltd (ASX: EVN), and Telix Pharmaceuticals Ltd (ASX: TLX).

The post Canaccord Genuity has just added these two ASX 200 shares to its best ideas list appeared first on The Motley Fool Australia.

More reading

• Which are the best ASX shares to buy now for FY27?
• 3 ASX 200 shares that could be too good to ignore in June
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX 200 shares today
• 3 ASX 200 tech shares to buy now: expert

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Technology One and Telix Pharmaceuticals. The Motley Fool Australia has recommended Technology One and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.